암 생물학적 요법 시장 규모, 점유율, 성장 분석 : 제품별, 암 유형별, 단계별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)

Global Cancer Biological Therapy Market size was valued at USD 85.06 billion in 2023 and is poised to grow from USD 91.27 billion in 2024 to USD 160.37 billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The global cancer biological therapy market is set for remarkable growth, fueled by the increasing incidence of cancer and the emergence of specialized treatment facilities. Experts are harnessing the power of nanotechnology to develop innovative therapeutic solutions, paving the way for advanced treatments and personalized patient care. The heightened emphasis on biological therapies, combined with technological advancements, is expected to transform cancer care, enabling more effective and tailored treatment options for patients worldwide. As research progresses and innovative solutions emerge, the market is poised for extraordinary expansion, enhancing the ongoing battle against this devastating disease. This convergence of innovation and growing patient needs positions the sector for unprecedented opportunities in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biological Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biological Therapy Market Segmental Analysis

Global Cancer Biological Therapy Market is segmented by Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users and region. Based on Product, the market is segmented into Monoclonal antibodies (MAB), Vaccines, Cancer growth blockers, Blood cell growth factors (BCGF) and Cytokines. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer and Prostate Cancer. Based on Phases, the market is segmented into Phase I, Phases II and Phases III. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Specialized Cancer Treatment Centers, Hospitals & Clinics and Retail Pharmacies. Based on End-Users, the market is segmented into Hospitals, Homecare, Speciality Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Biological Therapy Market

One of the primary factors driving the global cancer biological therapy market is the rising incidence of cancer cases across the globe. Recent statistics from the American Cancer Society indicate a concerning increase in Small Cell Lung Cancer (SCLC), predominantly affecting individuals aged 60 to 80. With an estimated annual death toll of about 30,000 from SCLC and lung cancer being the second most common type in both genders-resulting in 1.59 million fatalities as of 2012 per the World Health Organization-these sobering numbers highlight the urgent need for innovative cancer treatments. Consequently, there is a growing demand for cancer biological therapies to effectively combat this escalating health crisis.

Restraints in the Global Cancer Biological Therapy Market

One notable restraint in the Global Cancer Biological Therapy market is the high cost associated with cancer treatment options. The substantial expenses related to these therapies create a significant barrier for many patients, particularly those in rural regions who may struggle to access the necessary funds. This financial strain limits the ability of a large portion of the population to afford essential treatments, thus impeding overall market growth. As a result, the prohibitive pricing of cancer biological therapies remains a critical challenge that needs to be addressed to enhance accessibility and improve patient outcomes in the healthcare system.

Market Trends of the Global Cancer Biological Therapy Market

The global cancer biological therapy market is witnessing a prominent trend towards personalized and targeted therapies, driven by advancements in genomics and molecular biology. As researchers gain deeper insights into the unique genetic and molecular characteristics of various tumors, there is a growing demand for biologic treatments tailored to the specific genetic abnormalities or biomarkers present in patients' cancer cells. This focus on customization enhances treatment efficacy, minimizes adverse effects, and improves overall patient outcomes. By efficiently targeting the molecular underpinnings of tumors, these innovative therapies are transforming oncology, leading to significant market growth as healthcare systems increasingly adopt personalized approaches to cancer treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Patent Analysis

Global Cancer Biological Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Monoclonal antibodies (MAB)
  • Naked MAB
  • Conjugated MAB
  • Bispecific MAB
• Vaccines
  • Preventive vaccines
  • Therapeutic vaccines
• Cancer growth blockers
  • Tyrosine kinase inhibitors (TKI)
  • Proteasome inhibitors (PI)
  • mTOR inhibitors
• Blood cell growth factors (BCGF)
  • Lenograstim
  • Filgrastim
• Cytokines
  • Interferons
  • Interleukins

Global Cancer Biological Therapy Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

Global Cancer Biological Therapy Market Size by Phases & CAGR (2025-2032)

• Market Overview
• Phase I
• Phases II
• Phases III

Global Cancer Biological Therapy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Cancer Biological Therapy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Specialized Cancer Treatment Centers
• Hospitals & Clinics
• Retail Pharmacies

Global Cancer Biological Therapy Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Speciality Centres
• Others

Global Cancer Biological Therapy Market Size & CAGR (2025-2032)

• North America (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • US
  • Canada
• Europe (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations